These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20568660)

  • 1. [Cost-effectiveness analysis of methods for thromboprophylaxis after orthopedic surgery].
    Omel'ianovskiĭ VV; Zagorodniĭ NV; Margieva AV; Tsfasman FM
    Khirurgiia (Mosk); 2010; (5):72-81. PubMed ID: 20568660
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
    Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
    J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Budget impact analysis of Pradaxa thromboprophylaxis after total hip or total knee replacement].
    Bouée S; Zufferey P; Fagnani F
    Therapie; 2009; 64(4):249-57. PubMed ID: 19804705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
    Wolowacz SE; Roskell NS; Plumb JM; Clemens A; Noack H; Robinson PA; Dolan G; Brenkel IJ
    Thromb Haemost; 2010 Feb; 103(2):360-71. PubMed ID: 20024501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
    Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
    Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
    McCullagh L; Tilson L; Walsh C; Barry M
    Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
    Plumb JM; Clemens A; Monz BU
    Pharmacoeconomics; 2010; 28(9):781-2; author reply 782-4, 784-5. PubMed ID: 20824908
    [No Abstract]   [Full Text] [Related]  

  • 9. Dabigatran etexilate for prevention of venous thromboembolism.
    Eikelboom JE; Weitz JI
    Thromb Haemost; 2009 Jan; 101(1):2-4. PubMed ID: 19132179
    [No Abstract]   [Full Text] [Related]  

  • 10. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran versus enoxaparin after total hip replacement.
    Martins HS; Scalabrini-Neto A; Velasco IT
    Lancet; 2007 Dec; 370(9604):2002-3; author reply 2003-4. PubMed ID: 18083399
    [No Abstract]   [Full Text] [Related]  

  • 12. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Pharmacoeconomics; 2012 Feb; 30(2):137-46. PubMed ID: 22185183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
    Kwong LM
    Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.
    Garcia-Zozaya I
    J Ky Med Assoc; 1998 Apr; 96(4):143-8. PubMed ID: 9577110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
    Olsen J; Gundgaard J; Borris LC
    Ugeskr Laeger; 2005 May; 167(21):2273-9. PubMed ID: 15962854
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
    Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
    Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight heparin for the prevention and treatment of venous thromboembolism.
    Raskob GE
    Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery.
    Wolowacz SE
    Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):9-25. PubMed ID: 21351853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.
    Sullivan SD; Kwong L; Nutescu E
    Value Health; 2006; 9(2):68-76. PubMed ID: 16626410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
    McCullagh L; Walsh C; Barry M
    Pharmacoeconomics; 2012 Oct; 30(10):941-59. PubMed ID: 22667458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.